3-Amino-nonadecanon-(2) | 706748-07-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-Amino-nonadecanon-(2)
• 英文别名: 3-Aminononadecan-2-one
• CAS: 706748-07-4
• 化学式: C₁₉H₃₉NO
• 分子量: 297.525
• InChiKey: VHSOBGOXIPKVAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  21
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-Amino-nonadecanon-(2) 在 铂 盐酸 、 盐酸羟胺 、 氢气 、 sodium acetate 作用下， 以 乙醇 为溶剂， 生成 2.3-Diamino-nonadecan
  参考文献：
  名称：

  Necrosaminreihe, 5. Mitt.: Über eine einfache Synthese von aliphatischen α-Diaminen

  摘要：

  DOI：

  10.1007/bf00905250
• 作为产物：
  描述：

  3-Acetamino-nonadecanon-(2) 在 盐酸 作用下， 以 溶剂黄146 为溶剂， 生成 3-Amino-nonadecanon-(2)
  参考文献：
  名称：

  Necrosaminreihe, 5. Mitt.: Über eine einfache Synthese von aliphatischen α-Diaminen

  摘要：

  DOI：

  10.1007/bf00905250

文献信息

• APJ Receptor Compounds
  申请人：ANCHOR THERAPEUTICS, INC.

  公开号：US20160159861A1

  公开（公告）日：2016-06-09

  The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the it intracellular loop and domain of the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as cardiovascular diseases, (e.g., hypertension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.

  本发明涉及一般意义上的化合物，它们是G蛋白偶联受体apelin的变构调节剂（例如，负和正的变构调节剂，变构激动剂和激动-变构调节剂）。APJ受体化合物源自APJ受体的细胞内环和结构域。本发明还涉及使用这些APJ受体化合物和包含APJ受体化合物的药物组成物治疗与APJ受体调节相关的疾病和病况，例如心血管疾病（例如高血压和心力衰竭，如充血性心力衰竭）、癌症、糖尿病、干细胞移植、液体稳态、细胞增殖、免疫功能、肥胖症、转移性疾病和HIV感染。
• PTHR1 RECEPTOR COMPOUNDS
  申请人：Ren Yong

  公开号：US20110294738A1

  公开（公告）日：2011-12-01

  The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor PTHR1, also known as parathyroid hormone/parathyroid hormone related protein receptor. The PTHR1 compounds are derived from the intracellular loops and domains of the PTHR1 receptor. The invention also relates to the use of these PTHR1 receptor compounds and pharmaceutical compositions comprising the PTHR1 receptor compounds in the treatment of diseases and conditions associated with PTHR1 receptor modulation, such as osteoporosis; humoral hypercalcemia of malignancy; osteolytic and osteoblastic metastasis to bone; primary and secondary hyperparathyroidism associated increase in bone absorption; vascular calcification; psychiatric disorders and cognitive disorders associated with hyperparathyroidism; dermatological disorders; and excess hair growth.
• CXCR5 RECEPTOR COMPOUNDS
  申请人：McMurry Thomas J.

  公开号：US20110300167A1

  公开（公告）日：2011-12-08

  The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor CXCR5. The CXCR5 receptor compounds are derived from the intracellular loops and domains of the CXCR5 receptor. The invention also relates to the use of these CXCR5 receptor compounds and pharmaceutical compositions comprising the CXCR5 receptor compounds in the treatment of diseases and conditions associated with CXCR5 receptor modulation such as autoimmune diseases including lupus, HIV and rheumatoid arthritis, Primary Sjogren's Syndrome, chronic lymphocytic leukemia, Burkitt Lymphoma, colon and breast cancer tumor metastasis, Multiple Sclerosis and compromised immune function.
• CRF1 RECEPTOR COMPOUNDS
  申请人：McBride Edward

  公开号：US20110301087A1

  公开（公告）日：2011-12-08

  The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor for corticotrophin releasing hormone (or factor) receptor 1, also known as the CRF1, CRHR1, CRFR1, CRHR, CRF-R. The CRF1 receptor compounds are derived from the intracellular loops and domains of CRF1 receptor. The invention also relates to the use of these CRF1 receptor compounds and pharmaceutical compositions comprising the CRF1 receptor compounds in the treatment of diseases and conditions associated with CRF1 receptor modulation, such as inflammatory bowel disease (peripherally acting), irritable bowel syndrome (IBS), stress response (colonic motor activity), anxiety, sleep disorder, addictive behavior, acute and chronic neurodegeneration, preterm labor and pain.
• APJ RECEPTOR COMPOUNDS
  申请人：Janz Jay

  公开号：US20120028888A1

  公开（公告）日：2012-02-02

  The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.